Minimally-invasive Stage 1 to Protect against the Risk of Liver Failure in ALPPS for Hepatocellular Carcinoma
Matteo Serenari(Azienda USL di Bologna), Elio Jovine(Azienda USL di Bologna), Umberto Cillo(University of Padua), Marco Vivarelli(Marche Polytechnic University), Matteo Cescon(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Marco Massani(AULSS 2 Marca Trevigiana), Francesca Ratti(Vita-Salute San Raffaele University), Matteo Zanello(Ospedale Maggiore), Luca Aldrighetti(Vita-Salute San Raffaele University), Nicola Guglielmo(Ospedale di Latisana), M. Colledan(University Hospital Frankfurt), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Raffaele Dalla Valle(University of Parma), Bruno Nardo, Giuseppe Maria Ettorre(Carlo Forlanini Hospital), Federico Mocchegiani(Marche Polytechnic University), Fabrizio Di Benedetto(University of Modena and Reggio Emilia)
Cited by 0
Related Papers
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821